Document is current
Any future updates will be listed below
-
Authors
Brempelis, Katherine J https://orcid.org/0000-0002-9255-2608
Cowan, Courtney M
Kreuser, Shannon A
Labadie, Kevin P
Prieskorn, Brooke M
Lieberman, Nicole A P
Ene, Chibawanye I
Moyes, Kara W
Chinn, Harrison
DeGolier, Kole R
Matsumoto, Lisa R
Daniel, Sara K
Yokoyama, Jason K
Davis, Amira D
Hoglund, Virginia J
Smythe, Kimberly S
Balcaitis, Stephanie D
Jensen, Michael C
Ellenbogen, Richard G
Campbell, Jean S
Pierce, Robert H
Holland, Eric C
Pillarisetty, Venu G
Crane, Courtney A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02903914 at ClinicalTrials.govDocuments that mention this clinical trial
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
https://doi.org/10.1136/jitc-2024-010094
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
https://doi.org/10.1136/bmjonc-2023-000249
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
https://doi.org/10.1136/jitc-2020-001356
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
-
Funding
Funding for this research was provided by:
Sarah M. Hughes Foundation
National Cancer Institute (R01CA195718-02)
National Cancer Institute (U54CA193461-03)
Higgins Research Fund
United States Army Medical Research Acquisition Activity (CA150370P2)
Stand Up To Cancer
Pediatric Brain Tumor Research Fund
Washington Research Foundation
National Institute of Neurological Disorders and Stroke (R25NS079200)
- License Information
